Since the BCG vaccine does not offer complete protection against TB, vaccines have been designed to bolster BCG’s effectiveness. The industry has now transitioned from developing new alternatives, to selecting the best options currently available to advance into clinical testing.[5] MVA85A is characterized as the “most advanced ‘boost’ candidate” to date.[2]